دورية أكاديمية
أعرض في EDS

Impact of obesity on breast cancer recurrence and minimal residual disease.

التفاصيل البيبلوغرافية
العنوان: Impact of obesity on breast cancer recurrence and minimal residual disease.
المؤلفون: Ecker BL; Department of Surgery, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.; Department of Cancer Biology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA., Lee JY; Department of Cancer Biology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.; 2-PREVENT Translational Center of Excellence, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA.; The Abramson Family Cancer Research Institute, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 19104-6160, USA., Sterner CJ; Department of Cancer Biology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.; 2-PREVENT Translational Center of Excellence, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA.; The Abramson Family Cancer Research Institute, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 19104-6160, USA., Solomon AC; Department of Cancer Biology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.; 2-PREVENT Translational Center of Excellence, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA.; The Abramson Family Cancer Research Institute, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 19104-6160, USA., Pant DK; Department of Cancer Biology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.; 2-PREVENT Translational Center of Excellence, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA.; The Abramson Family Cancer Research Institute, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 19104-6160, USA., Shen F; Department of Cancer Biology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.; 2-PREVENT Translational Center of Excellence, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA.; The Abramson Family Cancer Research Institute, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 19104-6160, USA., Peraza J; Department of Cancer Biology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.; 2-PREVENT Translational Center of Excellence, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA.; The Abramson Family Cancer Research Institute, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 19104-6160, USA., Vaught L; Department of Cancer Biology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.; 2-PREVENT Translational Center of Excellence, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA.; The Abramson Family Cancer Research Institute, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 19104-6160, USA., Mahendra S; Department of Cancer Biology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.; 2-PREVENT Translational Center of Excellence, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA.; The Abramson Family Cancer Research Institute, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 19104-6160, USA., Belka GK; Department of Cancer Biology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.; 2-PREVENT Translational Center of Excellence, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA.; The Abramson Family Cancer Research Institute, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 19104-6160, USA., Pan TC; Department of Cancer Biology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.; 2-PREVENT Translational Center of Excellence, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA.; The Abramson Family Cancer Research Institute, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 19104-6160, USA., Schmitz KH; Penn State Cancer Institute, Penn State College of Medicine, Hershey, PA, 17033, USA., Chodosh LA; Department of Cancer Biology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA. chodosh@pennmedicine.upenn.edu.; 2-PREVENT Translational Center of Excellence, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA. chodosh@pennmedicine.upenn.edu.; The Abramson Family Cancer Research Institute, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 19104-6160, USA. chodosh@pennmedicine.upenn.edu.
المصدر: Breast cancer research : BCR [Breast Cancer Res] 2019 Mar 13; Vol. 21 (1), pp. 41. Date of Electronic Publication: 2019 Mar 13.
نوع المنشور: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: BioMed Central Ltd Country of Publication: England NLM ID: 100927353 Publication Model: Electronic Cited Medium: Internet ISSN: 1465-542X (Electronic) Linking ISSN: 14655411 NLM ISO Abbreviation: Breast Cancer Res Subsets: MEDLINE
أسماء مطبوعة: Publication: London, UK : BioMed Central Ltd
Original Publication: London, UK : Current Science, c1999-
مواضيع طبية MeSH: Breast Neoplasms/*mortality , Mammary Neoplasms, Experimental/*pathology , Neoplasm Recurrence, Local/*pathology , Obesity/*pathology, Animals ; Body Mass Index ; Body Weight ; Breast Neoplasms/pathology ; Cell Line, Tumor/transplantation ; Datasets as Topic ; Diet, High-Fat/adverse effects ; Disease-Free Survival ; Female ; Humans ; Mammary Neoplasms, Experimental/genetics ; Mammary Neoplasms, Experimental/mortality ; Mice, Obese ; Mice, Transgenic ; Neoplasm Recurrence, Local/mortality ; Neoplasm, Residual ; Obesity/etiology ; Receptor, ErbB-2/genetics ; Survival Analysis
مستخلص: Background: Obesity is associated with an increased risk of breast cancer recurrence and cancer death. Recurrent cancers arise from the pool of residual tumor cells, or minimal residual disease (MRD), that survives primary treatment and persists in the host. Whether the association of obesity with recurrence risk is causal is unknown, and the impact of obesity on MRD and breast cancer recurrence has not been reported in humans or in animal models.
Methods: Doxycycline-inducible primary mammary tumors were generated in intact MMTV-rtTA;TetO-HER2/neu (MTB/TAN) mice or orthotopic recipients fed a high-fat diet (HFD; 60% kcal from fat) or a control low-fat diet (LFD; 10% kcal from fat). Following oncogene downregulation and tumor regression, mice were followed for clinical recurrence. Body weight was measured twice weekly and used to segregate HFD mice into obese (i.e., responders) and lean (i.e., nonresponders) study arms, and obesity was correlated with body fat percentage, glucose tolerance (measured using intraperitoneal glucose tolerance tests), serum biomarkers (measured by enzyme-linked immunosorbent assay), and tissue transcriptomics (assessed by RNA sequencing). MRD was quantified by droplet digital PCR.
Results: HFD-Obese mice weighed significantly more than HFD-Lean and LFD control mice (p < 0.001) and had increased body fat percentage (p < 0.001). Obese mice exhibited fasting hyperglycemia, hyperinsulinemia, and impaired glucose tolerance, as well as decreased serum levels of adiponectin and increased levels of leptin, resistin, and insulin-like growth factor 1. Tumor recurrence was accelerated in HFD-Obese mice compared with HFD-Lean and LFD control mice (median relapse-free survival 53.0 days vs. 87.0 days vs. 80.0 days, log-rank p < 0.001; HFD-Obese compared with HFD-Lean HR 2.52, 95% CI 1.52-4.16; HFD-Obese compared with LFD HR 2.27, 95% CI 1.42-3.63). HFD-Obese mice harbored a significantly greater number of residual tumor cells than HFD-Lean and LFD mice (12,550 ± 991 vs. 7339 ± 2182 vs. 4793 ± 1618 cells, p < 0.001).
Conclusion: These studies provide a genetically engineered mouse model for study of the association of diet-induced obesity with breast cancer recurrence. They demonstrate that this model recapitulates physiological changes characteristic of obese patients, establish that the association between obesity and recurrence risk is causal in nature, and suggest that obesity is associated with the increased survival and persistence of residual tumor cells.
References: Nat Med. 2001 Feb;7(2):235-9. (PMID: 11175856)
Obes Res. 2001 Jul;9(7):414-7. (PMID: 11445664)
FASEB J. 2002 Mar;16(3):283-92. (PMID: 11874978)
J Natl Cancer Inst. 2002 Nov 20;94(22):1704-11. (PMID: 12441326)
Int J Obes Relat Metab Disord. 2002 Dec;26(12):1596-609. (PMID: 12461676)
Cancer Cell. 2002 Dec;2(6):451-61. (PMID: 12498714)
Genes Dev. 2003 Feb 15;17(4):488-501. (PMID: 12600942)
Breast Cancer Res Treat. 2003 Feb;77(3):205-15. (PMID: 12602920)
Diabetes Care. 2003 Aug;26(8):2383-8. (PMID: 12882866)
Int J Obes Relat Metab Disord. 2003 Sep;27(9):1066-71. (PMID: 12917712)
Clin Cancer Res. 2003 Nov 15;9(15):5699-704. (PMID: 14654554)
Eur J Endocrinol. 2004 Mar;150(3):243-55. (PMID: 15012607)
J Gen Intern Med. 2004 Apr;19(4):324-31. (PMID: 15061741)
Cancer Cell. 2004 Dec;6(6):577-86. (PMID: 15607962)
Nutr Cancer. 2004;50(2):174-80. (PMID: 15623464)
Arch Intern Med. 2005 Jun 13;165(11):1267-73. (PMID: 15956006)
Cancer Epidemiol Biomarkers Prev. 2005 Jul;14(7):1686-91. (PMID: 16030102)
Cancer Cell. 2005 Sep;8(3):197-209. (PMID: 16169465)
Breast Cancer Res Treat. 2006 Jun;97(3):245-54. (PMID: 16331345)
J Clin Oncol. 2006 Apr 20;24(12):1831-8. (PMID: 16549824)
Breast Cancer Res Treat. 2008 May;109(1):123-39. (PMID: 17578664)
Cancer Epidemiol Biomarkers Prev. 2007 Sep;16(9):1803-11. (PMID: 17855698)
Breast Cancer Res Treat. 2008 Sep;111(2):329-42. (PMID: 17939036)
BMJ. 2007 Dec 1;335(7630):1134. (PMID: 17986716)
Diabetes Metab. 2008 Feb;34(1):2-11. (PMID: 18093861)
Breast Cancer Res. 2007;9(6):R91. (PMID: 18162139)
Cancer Epidemiol Biomarkers Prev. 2008 Mar;17(3):614-20. (PMID: 18323413)
Clin Cancer Res. 2008 Mar 15;14(6):1718-25. (PMID: 18347172)
Nutr Cancer. 2008;60(4):534-41. (PMID: 18584488)
Breast Cancer Res Treat. 2010 Jan;119(1):145-53. (PMID: 19731015)
Obesity (Silver Spring). 2010 Apr;18(4):696-703. (PMID: 19798068)
Clin Cancer Res. 2009 Dec 1;15(23):7381-8. (PMID: 19920100)
Carcinogenesis. 2010 Jan;31(1):83-9. (PMID: 19969554)
J Clin Oncol. 2010 Jul 20;28(21):3411-5. (PMID: 20547990)
Breast Cancer Res Treat. 2010 Oct;123(3):627-35. (PMID: 20571870)
J Clin Oncol. 2011 Jan 1;29(1):25-31. (PMID: 21115856)
J Clin Oncol. 2011 Jan 1;29(1):32-9. (PMID: 21115858)
Lancet. 2011 Feb 12;377(9765):557-67. (PMID: 21295846)
CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90. (PMID: 21296855)
Clin Cancer Res. 2011 May 1;17(9):2967-76. (PMID: 21415211)
BMC Endocr Disord. 2011 Mar 22;11:7. (PMID: 21426570)
Breast Cancer Res Treat. 2011 Nov;130(2):587-97. (PMID: 21667121)
Nat Rev Cancer. 2011 Jun 16;11(7):523-32. (PMID: 21677677)
Am J Pathol. 2011 Aug;179(2):1030-40. (PMID: 21704006)
Anal Chem. 2011 Nov 15;83(22):8604-10. (PMID: 22035192)
Endocr Relat Cancer. 2012 Feb 13;19(1):57-68. (PMID: 22143497)
Mol Carcinog. 2013 Jun;52(6):446-58. (PMID: 22290600)
Breast Cancer. 2013 Oct;20(4):336-41. (PMID: 22367960)
PLoS One. 2012;7(4):e33308. (PMID: 22485140)
J Clin Oncol. 2012 May 20;30(15):1796-804. (PMID: 22508812)
Cancer Res. 2012 May 1;72(9):2314-26. (PMID: 22549948)
Breast Cancer Res Treat. 2012 Jul;134(2):769-81. (PMID: 22562122)
J Clin Oncol. 2012 Sep 10;30(26):3242-9. (PMID: 22649152)
Breast Cancer Res. 2012 Aug 14;14(4):R117. (PMID: 22889108)
Bioinformatics. 2013 Jan 1;29(1):15-21. (PMID: 23104886)
Endocr Relat Cancer. 2013 Jan 21;20(1):39-51. (PMID: 23152442)
Cancer Res. 2012 Dec 15;72(24):6490-501. (PMID: 23222299)
Cancer Med. 2012 Oct;1(2):275-88. (PMID: 23342276)
Endocr Rev. 2013 Jun;34(3):377-412. (PMID: 23475416)
Menopause. 2013 Aug;20(8):845-51. (PMID: 23481121)
Cancer. 2013 Jul 1;119(13):2447-54. (PMID: 23585192)
Cancer Cell. 2013 Jul 8;24(1):30-44. (PMID: 23770012)
Eur J Cancer. 2013 Nov;49(17):3588-97. (PMID: 23953055)
J Mammary Gland Biol Neoplasia. 2013 Dec;18(3-4):333-43. (PMID: 24122258)
Nat Genet. 2013 Dec;45(12):1439-45. (PMID: 24185512)
Breast Cancer Res. 2013 Nov 06;15(6):R105. (PMID: 24192331)
Bioinformatics. 2014 Apr 1;30(7):923-30. (PMID: 24227677)
Cancer Prev Res (Phila). 2014 Mar;7(3):310-8. (PMID: 24441676)
Lancet. 2014 Jul 12;384(9938):164-72. (PMID: 24529560)
Ann Oncol. 2014 Oct;25(10):1901-14. (PMID: 24769692)
Cancer Discov. 2014 Jul;4(7):790-803. (PMID: 24786206)
Front Oncol. 2014 Jul 08;4:175. (PMID: 25072025)
Cancer Res. 2014 Nov 1;74(21):6352-63. (PMID: 25164007)
J Clin Oncol. 2014 Nov 1;32(31):3568-74. (PMID: 25273035)
Annu Rev Med. 2015;66:281-96. (PMID: 25423596)
Genome Biol. 2014;15(12):550. (PMID: 25516281)
CA Cancer J Clin. 2015 Mar;65(2):87-108. (PMID: 25651787)
Breast Cancer Res Treat. 2015 Feb;150(1):127-39. (PMID: 25677740)
Breast Cancer Res Treat. 2015 Apr;150(2):231-42. (PMID: 25762475)
J Clin Invest. 2015 Jun;125(6):2484-96. (PMID: 25961456)
Nat Rev Cancer. 2015 Aug;15(8):484-98. (PMID: 26205341)
Surg Obes Relat Dis. 2016 Feb;12(2):257-63. (PMID: 26615868)
Clin Cancer Res. 2016 May 1;22(9):2283-9. (PMID: 26712688)
Oncologist. 2016 Apr;21(4):404-17. (PMID: 26865587)
JAMA. 2016 Jun 7;315(21):2284-91. (PMID: 27272580)
Int J Radiat Oncol Biol Phys. 2016 Sep 1;96(1):65-71. (PMID: 27511848)
J Immunol Methods. 2016 Oct;437:53-63. (PMID: 27555238)
N Engl J Med. 2016 Aug 25;375(8):794-8. (PMID: 27557308)
Sci Rep. 2017 Mar 28;7(1):491. (PMID: 28352127)
Cancer Res. 2017 May 1;77(9):2500-2511. (PMID: 28373182)
J Clin Oncol. 1998 Dec;16(12):3731-5. (PMID: 9850015)
J Natl Cancer Inst. 1999 Jan 6;91(1):80-5. (PMID: 9890174)
معلومات مُعتمدة: R01 CA098371 United States CA NCI NIH HHS; R01 CA148774 United States CA NCI NIH HHS; U54 CA155850 United States CA NCI NIH HHS; R01 CA143296 United States CA NCI NIH HHS; R01 CA208273 United States CA NCI NIH HHS
فهرسة مساهمة: Keywords: Breast cancer; High-fat diet; Obesity; Recurrence; Tumor dormancy
المشرفين على المادة: EC 2.7.10.1 (ERBB2 protein, human)
EC 2.7.10.1 (Receptor, ErbB-2)
تواريخ الأحداث: Date Created: 20190315 Date Completed: 20190722 Latest Revision: 20230930
رمز التحديث: 20240628
مُعرف محوري في PubMed: PMC6416940
DOI: 10.1186/s13058-018-1087-7
PMID: 30867005
قاعدة البيانات: MEDLINE
الوصف
تدمد:1465-542X
DOI:10.1186/s13058-018-1087-7